To investigate the prognostic importance of the metabolic syndrome (MetS) on incident cardiovascular disease (CVD).
Design
Prospective cohort study.
Methods
The study was based on 10-year follow-up of 3041 men and women aged 25-84 years without CVD or diabetes who participated in the 1994/1995 Busselton Health Survey. Hazards ratio (HRs) from Cox regression models were used to describe the effect of the MetS as a dichotomous classification and as the number of risk components on incident coronary heart disease (CHD), stroke and all CVD events.
Results
All cardiovascular and metabolic risk factors studied showed a strong association with the number of MetS risk components. The age-adjusted and sex-adjusted HR for the MetS was 1.70 (95% confidence interval: 1.15-2.51) for incident CHD but this was reduced to almost unity after adjustment for cardiovascular risk factors or the homoeostasis model assessment measure of insulin resistance. However, the number of MetS risk components remained significant (P < 0.01) with those having 3+ risk components with a three-fold increase in risk compared with those with no risk components (adjusted HR: 3.59, 95% confidence interval: 1.43-8.99).
ReavenGM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes1988; 37:1595–1607.
2.
GrundySMCleemanJIDanielsSRDonatoKAEckelRHFranklinBADiagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation2005; 112:e285–e290.
3.
AlbertiKGZimmetPZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med1998; 15:539–553.
4.
AlbertiKGMZimmetPShawJ. The metabolic syndrome – a new worldwide definition. Lancet2005; 366:1059–1062.
5.
HaffnerSTaegtmeyerH. Epidemic obesity and the metabolic syndrome. Circulation2003; 108:1541–1545.
6.
KahnRBuseJFerranniniESternM. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2005; 28:2289–2304.
7.
LakkaHMLaaksonenDELakkaTANiskanenLKKumpusaloETuomilehtoJThe metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA2002; 288:2709–2716.
8.
SternMPWilliamsKGonzalez-VillalpandoCHuntKJHaffnerSM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?Diabetes Care2004; 27:2676–2681.
9.
The Diabetes Epidemiology Collaborative analysis of diagnostic criteria in Europe (DECODE) study group.Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. Eur J Cardiovasc Prev Rehab2007; 14:192–199.
10.
DekkerJMGirmanCRhodesTNijpelsGStehouwerCDABouterLMMetabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation2005; 112:666–673.
11.
McNeillAMRosamondWDGirmanCJGoldenSHSchmidtMIEastHEThe metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care2005; 28:385–390.
12.
SundstromJRiserusUBybergLZetheliusBLithellHLindL. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ2006; 332:878–882.
13.
JeppesenJHansenTWRasmussenSIbsenHTorp-PedersenCMadsbadS. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: A population-based study. J Am Coll Cardiol2007; 49:2112–2119.
14.
NinomiyaTKuboMDoiYYonemotoKTanizakiYRahmanMImpact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: The Hisayama Study. Stroke2007; 38:2063–2069.
15.
GarniASWittBJHowardDEErwinPJGarniLASomersVKMetabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol2007; 49:403–414.
16.
FordES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care2005; 28:1769–1778.
17.
KnuimanMWJamrozikKWelbornTABulsaraMKDivitiniMLWhittallDE. Age and secular trends in risk factors for cardiovascular disease in Busselton. Aust J Public Health1995; 19:375–382.
18.
HungJMcQuillanBMChapmanCMLThompsonPLBeilbyJP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol2005; 25:1268–1273.
19.
MatthewsDRHoskerJPRudenskiASNaylorBATreacherDFTurnerRC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting insulin and glucose concentrations in man. Diabetologia1985; 28:412–419.
20.
WilsonPWFD'AgostinoRBLevyDBelangerAMSilbershatzHKannelWB. Prediction of coronary heart disease using risk factor categories. Circulation1998; 97:1837–1847.
21.
FordESGilesWHDietzWH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA2002; 287:356–359.
22.
HuGQiaoQTuomilehtoJBalkauBBorch-JohnsenKPyoralaKPrevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med2004; 164:1066–1076.
23.
LiWMaDLiuMLiuHFengSHaoZAssociation between metabolic syndrome and risk of stroke: A meta-analysis of cohort studies. Cerebrovasc Dis2008; 25:539–547.
24.
CullCAJensenCCRetnakaranRHolmanRR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus. UKPDS 78. Circulation2007; 116:2119–2126.
25.
MeigsJBRutterMKSullivanLMFoxCSD'AgostinoRBSrWilsonPWF. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care2007; 30:1219–1225.
26.
HanleyAJWagenknechtLED'AgostinoRBJrZinmanBHaffnerSM. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes2003; 52:2740–2747.
